| Part B: Supplementary Information Sheet (SIS) |
|
FR Recognition List Number
|
065
|
Date of Entry 12/22/2025
|
|
FR Recognition Number
|
2-310
|
| Standard | |
ASTM F748-25
Standard Practice for Selecting Generic Biological Test Methods for Materials and Devices |
|
Scope/Abstract1.1 This practice describes biological test methods (as listed in 2.1) which may be used in support of a biological evaluation of materials and medical devices according to end-use applications. Biological evaluation is a component of a broader safety evaluation and is conducted within an ISO 14971 risk management framework. ISO 10993-1 sets out the general principles and requirements for such an evaluation. A biological evaluation conducted according to ISO 10993-1 requires a consideration of the composition of the medical device and the review of pre-existing information pertinent to biological risks. In many cases this pre-existing information will be sufficient to establish safety without a need for additional testing. Only where existing information is insufficient it may be necessary to conduct further testing (see ISO 10993-1). The purpose of this document is to provide guidance on available and applicable test methods to support such testing activities if they are required.
1.2 The reader is cautioned that the area of biocompatibility testing is a rapidly evolving field, and improved methods are becoming available continuously, so this practice is a guideline. A thorough knowledge of current techniques and research is critical to a complete evaluation of new materials and medical devices.
1.3 Biological evaluation of materials and medical devices for human application is discussed. Tests include those performed on materials, final finished medical devices, and extracts. The current state of the art is included for all test procedures described.
1.4 The biocompatibility of materials used in single or multicomponent medical devices for human use depends to a large degree on the particular nature and duration of tissue contact during intended use. It is not possible to specify a set of test methods which will be necessary and sufficient to establish biocompatibility for all materials and applications. Because biological reactions caused by a material or a medical device can have different implications or raise different safety concerns depending on the type and duration of tissue contact of the medical device, each application must be evaluated for biocompatibility and any associated testing on its own merit.
1.5 The evaluation of tissue-engineered medical products (TEMPs) may, in some cases, involve different or additional testing beyond that conducted on non-TEMPs-based materials and medical devices. Where appropriate, these differences are discussed in this practice and additional tests described. For additional information, see reference standards published under the jurisdiction of the applicable TEMPs Subcommittees of F04.
|
|
| Extent of Recognition
|
Rationale for Recognition
| This standard is relevant to medical devices and is recognized on its scientific and technical merit and/or because it supports existing regulatory policies. |
|
Transition Period
| FDA recognition of ASTM F748-16 [Rec# 2-244] will be superseded by recognition of ASTM F748-25 [Rec# 2-310]. FDA will accept declarations of conformity, in support of premarket submissions, to [Rec# 2-244] until December 19, 2027. After this transition period, declarations of conformity to [Rec# 2-244] will not be accepted. |
|
Public Law, CFR Citation(s) and Procode(s)*
| 21 CFR 58 Good Laboratory Practise for Nonclinical Laboratory Studies |
|
Relevant FDA Guidance and/or Supportive Publications*
ISO 10993-12:2021: Biological evaluation of medical devices - Part 12: Sample preparation and reference materials.
Guidance for Industry and Food and Drug Administration Staff: Use of International Standard ISO 10993-1, "Biological evaluation of medical devices--Part 1: Evaluation and testing within a risk management process", Issued September 2023.
Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices - Guidance for Industry and Food and Drug Administration Staff, issued September 2018. |
|
| FDA Technical Contacts
|
| Standards Development Organization
|
| FDA Specialty Task Group (STG)
|
| *These are provided as examples and others may be applicable. |
